A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

Withdrawn before enrolling

Conditions studied: Hemangioma

In brief

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

Key facts

Study ID

NCT00974129

Run by

Yale University

People needed

0

Starts

2009-09-01

Expected to finish

2012-06-01

Last updated by the study team

2014-06-24

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Hemangioma must appear within one month prior to enrollment

You may not qualify if…

• Hemangioma appeared before one month prior to enrollment

Where it is running

• Yale Dermatology Associates — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.